No retraction, correction or concern found when last checked on Oct 19, 2026.
Histone H3K27 acetylation is dispensable for enhancer activity in mouse embryonic stem cells
Tiantian Zhang, Zhuqiang Zhang, Qiang Dong and 2 more
Genome Biology · 2020 · CC BY
doi:10.1186/s13059-020-01957-w
Abstract
Electronic supplementary material. Supplementary information accompanies this paper at 10.1186/s13059-020-01957-w.
Full text
From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.
Background
Enhancers are critical regulatory elements that control spatial and temporal gene expression, and they are demarcated by distinct chromatin modifications. In mammals, putative enhancers can be predicted by their local chromatin signatures, including H3K4me1 and H3K27ac. Among these enhancer marks, H3K27ac is of particular interest because it distinguishes active enhancers from poised ones. To date, a large body of literature has well established a role for H3K27ac in indicating enhancer activity. On the other hand, whether H3K27ac functionally determinates enhancer activity is less clear because it is difficult to selectively target H3K27ac at enhancers. Nevertheless, it has been reported that H3K27ac plays an active role in cell identity control.
Enrichment of histone variant H3.3 and high histone turnover are other enhancer features. Although mammalian H3.3 differs from canonical H3.1 by only five amino acids, H3.3 is deposited into specific chromatin regions by distinct histone chaperones and is enriched for active histone modifications such as H3K4me3 and H3K27ac. H3.3 is not essential for viability in Drosophila. However, complete loss of H3.3 in mice is embryonic lethal at an early stage and even cellular lethal as a result of mitotic defects. Replacing lysine 27 with a nonmodifiable residue in one of the two genes encoding H3.3 in Drosophila causes male lethality and infertility and reduced global H3K27ac levels. A similar reduction in H3K27ac levels was also observed in mouse embryonic stem cells (ESCs) depleted of H3.3. Therefore, we reasoned that targeting enhancer H3K27ac might be achievable by mutating both H3.3-encoding genes (H3f3a and H3f3b) and producing a homogenous population of H3.3 lysine 27-to-arginine (K27R) mutant histones in mouse ESCs.
Results and discussion
We utilized the CRISPR-Cas9 gene editing system to sequentially introduce mutations in both endogenous alleles of H3f3a and H3f3b, and the engineered mouse ESC clones were confirmed by Sanger sequencing (Additional file 2: Figure S1). We chose two H3.3K27R clones (Mut18 and Mut43) with similar H3.3 protein levels to those in wild-type (WT) ESCs for further investigations (Additional file 2: Figure S2a). The colony morphology and expression levels of key pluripotent genes were unchanged in H3.3K27R mutant cells compared with WT cells (Additional file 2: Figure S2b, S2c). We first measured the global H3K27ac level by Western blot analysis and observed a moderately reduced bulk H3K27ac level in mutant cells (Fig. 1a), which is expected because mouse ESCs contain much higher levels of canonical H3 histones, which remain possible to be acetylated at K27.
We then performed chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) experiments in WT and the two H3.3K27R mutant lines, and all experiments were performed in biological duplicates. H3K27ac occupancy in the mutant lines displayed an extensive genome-wide loss (Additional file 2: Figure S3). We identified 13,037 H3K27ac peaks showing a more than twofold significant reduction in mutant cells, in contrast to only 40 H3K27ac peaks showing a more than twofold significant increase in mutant cells (Fig. 1b). We defined putative enhancers in WT ESCs with H3K4me1 ChIP-seq and observed that approximately 80% of enhancer-overlapping H3K27ac peaks exhibited significantly reduced H3K27ac in mutant lines using a twofold change cut-off, while the ratio was approximately 30% for H3K27ac peaks around promoters (Fig. 1c). These results indicate that we successfully targeted the enhancer H3K27ac level as we had planned. The different effects at enhancers and promoters suggest that H3.3 occupancy around active enhancers should be much higher than that at TSS regions. We analyzed recently published H3.3 ChIP-seq data and indeed confirmed our prediction (Additional file 2: Figure S4).
We then divided all enhancers into active and poised groups according to the H3K27ac signal in WT cells. Strikingly, H3K27ac was almost completely depleted at active enhancers in H3.3K27R mutant ESCs (Fig. 1d). These results suggest that the vast majority of H3K27ac at active enhancers is on H3.3 and not on H3.1 or H3.2. This is consistent with high nucleosome turnover and high H3.3 occupancy (, Additional file 2: Figure S4) at enhancers. In contrast, H3K27ac signals around gene transcription start sites (TSSs) were moderately decreased in the mutants (Fig. 1e). H3.3 has been reported to promote the establishment of H3K27me3 at the bivalent promoters of developmentally regulated genes. We mapped the distribution of H3K27me3 by ChIP-seq in WT and H3.3K27R mutant ESC lines and observed that H3K27me3 signals were moderately declined at bivalent regions (Additional file 2: Figure S5a), which could be attributed to the incorporation of the nonmodifiable H3.3K27R mutant histone. On the other hand, the genome-wide distribution of H3K27me3 was mostly unchanged in response to the H3.3K27R mutation (Additional file 2: Figure S5b). We also specifically looked at the enhancers of important pluripotent genes, such as Pou5f1 (encoding Oct4) and Nanog, and observed a substantial reduction in H3K27ac (Fig. 1f).
To evaluate the functional impact of the H3.3K27R mutation on transcription, we performed mRNA-seq in WT and the two mutant lines in biological duplicates. Despite the global reduction in H3K27ac in H3.3K27R mutant ESCs, the transcriptome change was minimal; in fact, the r value was 0.98 between the WT and mutant cells (Fig. 2a). Although 146 and 391 genes were upregulated or downregulated in H3.3K27R mutant ESCs, respectively (Fig. 2a), and the changes were highly consistent between the two individual H3.3K27R mutant ESC lines (Additional file 2: Figure S6), no obvious relationship was observed between H3K27ac and transcription change (see below). To define the target genes of active enhancers, we applied an activity-by-contact model to predict enhancer-gene connections in the WT mouse ESCs. We associated 8911 genes with H3K27ac-marked active enhancers and observed only 53 upregulated and 195 downregulated genes in H3.3K27R mutant ESCs (Fig. 2b). Moreover, H3K27ac at enhancers of both the upregulated and downregulated genes was decreased (Fig. 2c). Similar events were observed for H3K27ac peaks around TSSs and their associated genes (Fig. 2d, e). Our results indicate that gene transcription is not sensitive to the dramatic decrease in H3K27ac at gene enhancers. Moreover, even though H3K27ac was greatly reduced at the enhancer regions of Pou5f1 and Nanog, no transcriptional changes were observed in the mutant ESCs (Fig. 1f).
The activity-by-contact model outperformed other methods in predicting enhancer-gene connections, but the predicted associations are still not unequivocal. Super enhancers encompass large chromatin domains and harbor enormous amounts of H3K27ac and are associated with pluripotency genes in mouse ESCs. The associations between super enhancers and their target genes are much more clearly defined in mouse ESCs. Therefore, we specifically examined super enhancer-associated genes, although H3K27ac levels were dramatically decreased at the super enhancers, few transcriptional changes occurred (Additional file 2: Figure S7). Only two genes, Lefty2 and Fam25c, exhibited mild upregulation, and none of the genes exhibited significant downregulation (Additional file 2: Figure S7b, S7c). These results again indicate that H3K27ac is not functionally required for transcription, even for genes associated with super enhancers, in mouse ESCs.
To offer an explanation, we analyzed other features of enhancers in H3.3K27R mutant ESCs. H3K4me1 showed a mild decrease at enhancers and around H3K27ac-enriched TSSs (Additional file 2: Figure S8). Chromatin accessibility as determined by the amount of transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) revealed that the open state of enhancers and TSSs remained largely unchanged in H3.3K27R mutant ESCs (Fig. 2f, g), suggesting that enhancer identities in mouse ESCs are well maintained. Similarly, H3K4me3 was well maintained at H3K27ac-occupied TSSs in H3.3K27R mutant ESCs (Additional file 2: Figure S9). Multiple lysine residues can be acetylated, and these acetylation events, such as H3K9ac, H3K18ac, H3K23ac, H3K122ac, and histone H4 acetylation, tend to be coenriched. ChIP-seq profiling of H3K9ac, H3K18ac, H3K122ac, H4K5ac, and H4K8ac in WT and H3.3K27R mutant ESCs showed that these acetylation events were generally unchanged or only mildly affected at enhancers and TSSs (Additional file 2: Figure S10). Lysine acetylation events neutralize positive charges on histone tails, attenuate the interaction between histone tails and DNA, and lead to chromatin opening. H3K27ac is catalyzed by cyclic AMP response element-binding protein (CBP) and its paralogous protein P300, which also catalyze acetylation at many other histone lysine residues. Therefore, a synergistic action by multiple acetylation events at these different residues is much more crucial for transcription than acetylation at a solo site, such as H3K27. Consistently, RNA Pol II occupancy was unaltered around the TSSs (Fig. 2h, i), reflecting globally undisturbed transcription initiation.
Among multiple histone lysine acetylation sites, H3K27ac is specifically utilized as a marker for active enhancers. Using chromatin accessibility as a proxy for promoter and enhancer activity, we analyzed the correlations between each individual acetylation ChIP-seq and ATAC-seq signals at promoters and enhancers. Pearson correlation revealed that indeed H3K27ac is the best marker associated with active enhancer, but acetylation events at other lysine residues also display positive correlations with enhancer accessibility (Additional file 2: Figure S11).
Conclusions
Our results clearly indicate that the depletion of H3K27ac does not affect enhancer activity in mouse ESCs, whether it may have a stronger impact in other cells types such as somatic cells and cancer cells can be addressed using the same approach in future.
H3K27ac is and remains to be the best marker for enhancer indication. However, the depletion of H3K27ac at enhancer regions does not affect chromatin accessibility, gene transcription, and self-renewal of mouse ESCs. Therefore, maintenance of enhancer activity does not solely depend on H3K27ac; instead, H3K27ac has to work in concert with acetylation events on other histone lysine residues.
Cell culture and editing
J1 mouse ES cells were cultured in standard ES medium in the presence of feeder cells. Prior to harvesting, ESCs were cultured under the feeder-free condition for two passages to remove feeder cells.
Gene editing was performed with CRISPR-Cas9 gene editing technology. Each gene was targeted by two sgRNAs: H3f3a: 5′-GCTTAATTAGCGCTCGACAC-3′, 5′-TACTAGTTGACTATACTAGA-3′; H3f3b: 5′-TGGTGGCCAGCTGTTTGCGG-3′, 5′-AAGCGCGCCCTCTACCGGCG-3′. Detailed strategies are presented in Additional file 1.
ChIP-seq
ChIP experiments were performed as described previously with minor modifications. In brief, cells were cross-linked with 1% formaldehyde for 9 min at room temperature. For RNA Pol II ChIP, cells were pre-cross-linked with 0.2 mM disuccinimidyl glutarate (DSG; ProteoChem, c1104) for 30 min at room temperature. Chromatin shearing was assisted with additional 0.1% sodium deoxycholate (0.5% for dual cross-linked samples). Adequate antibodies as indicated in the manufacturers’ instructions were used for precipitations. Library construction for deep sequencing was performed with KAPA Hyper Prep Kit (KAPA, KK8504) according to the manufacturers’ instructions.
Antibodies
Antibodies against histone H3 (Abcam, ab1791), H3.3 (Millipore, 09-838), H3K4me1 (Active Motif, 39297), H3K4me3 (Millipore, 07-473), H3K9ac (Abcam, ab4441), H3K18ac (Active Motif, 39755), H3K27ac (Active Motif, 39133), H3K27me3 (Cell Signaling, 9733S), H3K122ac (Abcam, ab33309), histone H4 (ABclonal, A1131), H4K5ac (Active Motif, 39699), H4K8ac (Active Motif, 61103), and RNA Pol II (Active Motif, 39097) were obtained commercially.
Sequencing and bioinformatic analysis
ChIP-seq and ATAC-seq libraries were sequenced (PE150) with Illumina NovaSeq 6000 (see Additional file 3: Table S1). mRNA-seq libraries were sequenced with the MGIDEQ-2000 (PE150) (see Additional file 3: Table S3). Mouse genome sequences (mm10) and Drosophila genome sequences (dm6) were concatenated to be used as the reference genome. H3.3 ChIP-seq data were downloaded from GEO database under the accession number of GSE117035. Please see Additional file 1 for the detailed data analysis strategies.
References 37
- 1.
Serfling E, Jasin M, Schaffner W. Enhancers and eukaryotic gene transcription. Trends Genet. 1985;1:224-230.
Not in our library10.1016/0168-9525(85)90088-5
- 2.
Calo E, Wysocka J. Modification of enhancer chromatin: what, how, and why? Mol Cell. 2013;49:825-837.
Not in our library10.1016/j.molcel.2013.01.038
- 3.
Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet. 2007;39:311-318.
Not in our library10.1038/ng1966
- 4.
Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, Harp LF, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature. 2009;459:108-112.
Not in our library10.1038/nature07829
- 5.
Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008;40:897-903.
Not in our library10.1038/ng.154
- 6.
Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, Steine EJ, et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A. 2010;107:21931-21936.
Not in our library10.1073/pnas.1016071107
- 7.
- 8.
Mito Y, Henikoff JG, Henikoff S. Genome-scale profiling of histone H3.3 replacement patterns. Nat Genet. 2005;37:1090-1097.
Not in our library10.1038/ng1637
- 9.
Goldberg AD, Banaszynski LA, Noh K-M, Lewis PW, Elsaesser SJ, Stadler S, et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell. 2010;140:678-691.
Not in our library10.1016/j.cell.2010.01.003
- 10.
Chen P, Zhao J, Wang Y, Wang M, Long H, Liang D, et al. H3.3 actively marks enhancers and primes gene transcription via opening higher-ordered chromatin. Genes Dev. 2013;27:2109-2124.
Not in our library10.1101/gad.222174.113
- 11.
- 12.
Huang C, Zhu B. H3.3 turnover: a mechanism to poise chromatin for transcription, or a response to open chromatin? Bioessays. 2014;36:579-584.
Not in our library10.1002/bies.201400005
- 13.
- 14.
Deaton AM, Gomez-Rodriguez M, Mieczkowski J, Tolstorukov MY, Kundu S, Sadreyev RI et al. Enhancer regions show high histone H3.3 turnover that changes during differentiation. eLife. 2016;5:e15316.
Not in our library10.7554/elife.15316
- 15.
Chow Cheok‐Man, Georgiou Andrew, Szutorisz Henrietta, Maia e Silva Alexandra, Pombo Ana, Barahona Isabel, Dargelos Elise, Canzonetta Claudia, Dillon Niall. Variant histone H3.3 marks promoters of transcriptionally active genes during mammalian cell division. EMBO reports. 2005;6(4):354-360.
Not in our library10.1038/sj.embor.7400366
- 16.
Dunleavy EM, Almouzni G, Karpen GH. H3.3 is deposited at centromeres in S phase as a placeholder for newly assembled CENP-A in G(1) phase. Nucleus. 2011;2:146-157.
Not in our library10.4161/nucl.2.2.15211
- 17.
Tagami H, Ray-Gallet D, Almouzni G, Nakatani Y. Histone H3.1 and H3.3 complexes mediate nucleosome assembly pathways dependent or independent of DNA synthesis. Cell. 2004;116:51-61.
Not in our library10.1016/s0092-8674(03)01064-x
- 18.
Ray-Gallet D, Woolfe A, Vassias I, Pellentz C, Lacoste N, Puri A, et al. Dynamics of histone H3 deposition in vivo reveal a nucleosome gap-filling mechanism for H3.3 to maintain chromatin integrity. Mol Cell. 2011;44:928-941.
Not in our library10.1016/j.molcel.2011.12.006
- 19.
McKittrick E, Gafken PR, Ahmad K, Henikoff S. Histone H3.3 is enriched in covalent modifications associated with active chromatin. Proc Natl Acad Sci USA. 2004;101:1525-1530.
Not in our library10.1073/pnas.0308092100
- 20.
Hake SB, Garcia BA, Duncan EM, Kauer M, Dellaire G, Shabanowitz J, et al. Expression patterns and post-translational modifications associated with mammalian histone H3 variants. J Biol Chem. 2006;281:559-568.
Not in our library10.1074/jbc.m509266200
- 21.
Loyola A, Bonaldi T, Roche D, Imhof A, Almouzni G. PTMs on H3 variants before chromatin assembly potentiate their final epigenetic state. Mol Cell. 2006;24:309-316.
Not in our library10.1016/j.molcel.2006.08.019
- 22.
Hodl M, Basler K. Transcription in the absence of histone H3.3. Curr Biol. 2009;19:1221-1226.
Not in our library10.1016/j.cub.2009.05.048
- 23.
Sakai A, Schwartz BE, Goldstein S, Ahmad K. Transcriptional and developmental functions of the H3.3 histone variant in Drosophila. Curr Biol. 2009;19:1816-1820.
Not in our library10.1016/j.cub.2009.09.021
- 24.
Jang CW, Shibata Y, Starmer J, Yee D, Magnuson T. Histone H3.3 maintains genome integrity during mammalian development. Genes Dev. 2015;29:1377-1392.
Not in our library10.1101/gad.264150.115
- 25.
Leatham-Jensen M, Uyehara CM, Strahl BD, Matera AG, Duronio RJ, McKay DJ. Lysine 27 of replication-independent histone H3.3 is required for Polycomb target gene silencing but not for gene activation. PLoS Genet. 2019;15:e1007932.
Not in our library10.1371/journal.pgen.1007932
- 26.
Martire S, Gogate AA, Whitmill A, Tafessu A, Nguyen J, Teng YC, et al. Phosphorylation of histone H3.3 at serine 31 promotes p300 activity and enhancer acetylation. Nat Genet. 2019;51:941-946.
Not in our library10.1038/s41588-019-0428-5
- 27.
Wang Y, Long H, Yu J, Dong L, Wassef M, Zhuo B, et al. Histone variants H2A.Z and H3.3 coordinately regulate PRC2-dependent H3K27me3 deposition and gene expression regulation in mES cells. BMC Biol. 2018;16:107.
Not in our library10.1186/s12915-018-0568-6
- 28.
Banaszynski LA, Wen D, Dewell S, Whitcomb SJ, Lin M, Diaz N, et al. Hira-dependent histone H3.3 deposition facilitates PRC2 recruitment at developmental loci in ES cells. Cell. 2013;155:107-120.
Not in our library10.1016/j.cell.2013.08.061
- 29.
Fulco CP, Nasser J, Jones TR, Munson G, Bergman DT, Subramanian V, et al. Activity-by-contact model of enhancer-promoter regulation from thousands of CRISPR perturbations. Nat Genet. 2019;51:1664-1669.
Not in our library10.1038/s41588-019-0538-0
- 30.
Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153:307-319.
Not in our library10.1016/j.cell.2013.03.035
- 31.
Eberharter A, Becker PB. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep. 2002;3:224-229.
Not in our library10.1093/embo-reports/kvf053
- 32.
Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature. 1996;384:641-643.
Not in our library10.1038/384641a0
- 33.
Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional Coactivators p300 and CBP are histone Acetyltransferases. Cell. 1996;87:953-959.
Not in our library10.1016/s0092-8674(00)82001-2
- 34.
Sen P, Lan Y, Li CY, Sidoli S, Donahue G, Dou Z, et al. Histone acetyltransferase p300 induces de novo super-enhancers to drive cellular senescence. Mol Cell. 2019;73:684-698.
Not in our library10.1016/j.molcel.2019.01.021
- 35.
Yin Y, Yan P, Lu J, Song G, Zhu Y, Li Z, et al. Opposing roles for the lncRNA haunt and its genomic locus in regulating HOXA gene activation during embryonic stem cell differentiation. Cell Stem Cell. 2015;16:504-516.
Not in our library10.1016/j.stem.2015.03.007
- 36.
Xiong J, Zhang Z, Chen J, Huang H, Xu Y, Ding X, et al. Cooperative action between SALL4A and TET proteins in stepwise oxidation of 5-methylcytosine. Mol Cell. 2016;64:913-925.
Not in our library10.1016/j.molcel.2016.10.013
- 37.
Zhang T, Zhang Z, Dong Q, Xiong J, Zhu B. The role of histone H3K27 acetylation for enhancer activity in embryonic stem cells. GSE141525. Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE141525 (2020). Accessed 9 Feb 2020.
Not in our library
Cited by papers we hold 6
- Systematic epigenome editing captures the context-dependent instructive function of chromatin modifications · 2024No notice
- Bacon: a comprehensive computational benchmarking framework for evaluating targeted chromatin conformation capture-specific methodologies · 2022Not checked
- Recent advances in the developmental origin of neuroblastoma: an overview · 2022No notice
- CBP/p300 and HDAC activities regulate H3K27 acetylation dynamics and zygotic genome activation in mouse preimplantation embryos · 2022No notice
- Genome-wide mapping of G-quadruplex structures with CUT&Tag · 2021No notice
- The transcription factor activity gradient (TAG) model: contemplating a contact-independent mechanism for enhancer–promoter communication · 2021No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.